# A Clinical Trial to Assess the Clinical Benefit of SSR411298 as Adjunctive Treatment for Persistent Cancer Pain

> **NCT01439919** · PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 5 (actual)

## Conditions studied

- Pain
- Breakthrough Cancer Pain

## Interventions

- **DRUG:** SSR411298
- **DRUG:** Placebo (for SSR411298)

## Key facts

- **NCT ID:** NCT01439919
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-01
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** due to strategic reasons
- **Last updated:** 2013-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01439919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01439919, "A Clinical Trial to Assess the Clinical Benefit of SSR411298 as Adjunctive Treatment for Persistent Cancer Pain". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01439919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*